Open Orphan plc (ORPH) Investor Event Attendance and Presentation

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce that the Company will be attending and presenting at The London Investor Show at Novotel London West, London, W6 8DR this Friday 25th October 2019. Maurice Treacy, Open Orphan’s Chief Commercial Officer, will be in attendance and will be presenting in Conference […]

Open Orphan #ORPH signs strategic collaboration agreement with Empiric Logic

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce it has signed a new strategic collaboration agreement (“the Collaboration”) with Empiric Logic to build on the earlier work performed by Open Orphan and complete the build out of Open Orphan’s Health Data platform, Europe’s first rare disease, advocacy-led genomic database. Empiric […]

Open Orphan #ORPH presents at Shares Investor Evening, Manchester

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce that the Company will be attending and presenting at Shares Investor Evening at Macdonald Manchester Hotel, Manchester, M1 2PG from 18:00 on Thursday 10th October. Cathal Friel, Open Orphan’s Chief Executive Officer, will be in attendance and will be presenting to update existing and potential investors on […]

Open Orphan (ORPH) – CRUX Asset Management Ltd increase Holding(s) in Company

TR-1: Standard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: Open Orphan PLC 1b. Please indicate if the issuer is […]

Open Orphan #ORPH – Interim Results for 6 months ended 30 June 2019

Open Orphan, a European-focused, rare and orphan drug consulting services platform, announces its interim results for the six months ended 30 June 2019. Financial Highlights below (and in note 3 of the reported financial statements) reflect the interim results of Venn Life Sciences (“Venn”) prior to the reverse takeover by Open Orphan on the 28 June […]